Skip to main content
Premium Trial:

Request an Annual Quote

Leica Developing CDx for Bristol-Myers Squibb Drugs

NEW YORK (GenomeWeb) — Danaher's Leica Biosystems said today that it has made a deal with Bristol-Myers Squibb to collaborate in developing companion diagnostics to predict which patients will respond to BMS-developed targeted therapies.

Leica said it will create fully automated tissue-based companion diagnostics to run on its Bond automated staining system. These tests will select patients for treatment with pharmaceuticals already developed, or to be developed, by BMS in the future.

The company did not disclose specific drugs that will fall under the collaboration or other terms of the agreement.